Result:Very Good· Market: Flat#Broad based#Margin expansion
| Metric | Value (₹ Cr) | Q1 FY26 |
|---|---|---|
| Revenue | 33.72 | 42.8% |
| Total Income | 34.29 | 37.4% |
| Expenditure | 27.69 | 31.7% |
| PBT | 6.61 | 67.9% |
| Net Profit | 5.03 | 64.2% |
| OPM | 25.25% | 3.36pp |
| NPM | 14.67% | 2.40pp |
| EPS | 4.22 | 58.6% |
Revenue grew 42.8% YoY with OPM expanding ~340bps (21.9%→25.3%), driving 64.2% adjusted PAT growth — a core-business-led standout for pharma, not a one-off.
Informational and educational content only. Not investment advice.